(Q37447522)

English

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

scientific article published on 28 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Hegedus

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C Ozvegy-Laczka

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Apáti

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

M Magócsi

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

K Német

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

L Orfi

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

G Kéri

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

M Katona

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Z Takáts

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Váradi

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

G Szakács

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

B Sarkadi

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

28 September 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

British Journal of Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

158

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1153-1164

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Flying under the radar: the new wave of BCR-ABL inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Tumour stem cells and drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

23 August 2017

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

14 September 2017

Calcein accumulation as a fluorometric functional assay of the multidrug transporter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

26 June 2018

Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

2 September 2018

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2785536

2 September 2018

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2009.00383.X

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2009.00383.X

21 January 2018

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2009.00383.X

21 January 2018

Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19785662

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19785662

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19785662

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1476-5381.2009.00383.X

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37447522&oldid=1584492348"